Intriguingly, a recent paper identified PBRM1 loss as a potential genomic biomarker for the treatment response to these immune checkpoint inhibitors [68–69] and others suggested otherwise [70–71], which needs further validation facing the daunting intratumor heterogeneity of ccRCC. The gene discussed is PBRM1; the disease is nonpapillary renal cell carcinoma.